The Role of c-Cbl in Energy Homeostasis

Information

  • Research Project
  • 7394951
  • ApplicationId
    7394951
  • Core Project Number
    F32DK075249
  • Full Project Number
    5F32DK075249-03
  • Serial Number
    75249
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/2006 - 18 years ago
  • Project End Date
    3/31/2009 - 15 years ago
  • Program Officer Name
    FINKELSTEIN, DAVID B.
  • Budget Start Date
    4/1/2008 - 16 years ago
  • Budget End Date
    3/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    3
  • Suffix
  • Award Notice Date
    1/24/2008 - 16 years ago

The Role of c-Cbl in Energy Homeostasis

Recent studies in this lab have identified c-Cbl as a key regulator of whole body energy expenditure and adiposity in mice. Ablation of c-Cbl in mice results in a desirable phenotype of reduced adiposity, increased lean body mass, small adipocytes, and increased energy expenditure despite hyperphagia. These mice illustrate a role for c-Cbl in an unknown facet of fuel metabolism that is integrally linked to body weight regulation. The majority of these metabolic changes occur in muscle and fat tissue, therefore the specific aims for this proposal are to 1) identify the tissue type that drives the c-Cbl -/- phenotype and 2) determine the molecular mechanism by which c-Cbl ablation results in increased fatty acid oxidation and reduced adiposity. Dissecting the c-Cbl -/- phenotype will illustrate the role of this protein in the molecular control of energy expenditure and have therapeutic applications in diabetes and obesity. The exciting aspect of these studies is that the molecular control of energy expenditure in mammals is a newly evolving field and the precise wiring diagram for this pathway has yet to be established. This study will identify novel inroads into this pathway and may pave the way for our understanding of mitochondrial energy expenditure.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    F32
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    41796
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:41796\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GARVAN INSTITUTE OF MEDICAL RESEARCH
  • Organization Department
  • Organization DUNS
    751954603
  • Organization City
    SYDNEY
  • Organization State
  • Organization Country
    AUSTRALIA
  • Organization Zip Code
    2010
  • Organization District
    AUSTRALIA